150 results about "Lidocaine Hydrochloride" patented technology

Disclosed is a method of inducing topical anesthesia in a tissue or organ of an animal comprising providing an aqueous gel formulation comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed are a transdermal patch comprising the aqueous gel formulation suitable for applying on the skin of a patient and a method of controlling pain therewith.

Disclosed is a stable aqueous gel formulation suitable for topical use comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed is a method of inducing topical anesthesia on a tissue or organ, e.g., the eye, of an animal comprising providing a stable aqueous gel formulation comprising water, an anesthetic, a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile, and topically administering an effective amount of the aqueous gel formulation to the tissue or organ of the animal.

Disclosed is a stable aqueous gel formulation suitable for topical use comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed is a method of inducing topical anesthesia on a tissue or organ, e.g., the eye, of an animal comprising providing a stable aqueous gel formulation comprising water, an anesthetic, a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile, and topically administering an effective amount of the aqueous gel formulation to the tissue or organ of the animal.

A compound analgesic for bone fracture, injury, ecchymoma, nerval pain, etc is composed of antisticking layer, hydrophilic gel layer and substrate layer. Said hydrophilic gel layer consists of the medicine prepared from lidocaine hydrochloride and superfine notoginseng powder or its extract and the matrix prepared from gelatin, carboxymethyl cellulose sodium, polyvinyl pyrrolidone, etc.

The invention provides a method for preparing lidocaine hydrochloride, and belongs to the technical field of anesthetic synthesis. The method comprises the following steps: by taking 2,6-xylenol as a raw material, Pd/C as a main catalyst and 2,6-dimethylcyclohexanone as a promoter, performing liquid phase amination with ammonia water at high temperature, thereby obtaining a midbody 2,6-dimethylaniline; enabling sodium methylate, 2,6-dimethylaniline and N,N-lignocaine methyl acetate as raw materials to react at 90-95 DEGC, distilling while reaction is performed to remove methanol till no methanol can be evaporated out, continuously reacting for 30 minutes, cooling to the room temperature, adding dichloroethane, washing with water, and leaving to stand to layer, thereby obtaining an organic layer, namely, a lidocaine based dichloroethane solution; further adding hydrochloric acid into the lidocaine based dichloroethane solution, adjusting the pH value to be 3.5-4 by using hydrogen chloride, adding activated carbon to reflux for 20-40 minutes, filtering, concentrating the filtrate, cooling, crystallizing, and dying, thereby obtaining lidocaine hydrochloride. The lidocaine hydrochloride prepared by using the method is simple in synthesis process and high in product purity, that is, the purity can be greater than 99%, and the total yield is greater than 84%.

The invention belongs to the technical field of medicine, in particular to a drug composition of gargle which contains sodium dichlorophenolate and can relieve pain and be anti-inflammatory for the oral inflammation disease; wherein the drug composition comprises the following components by percentage: 0.10 to 30 percent of sodium dichlorophenolate hydroxypropyl-Beta-cyclodextrin inclusion (equal to 0.065 to 0.20 percent of concentration of sodium dichlorophenolate), 0.01 to 0.10 percent of lidocaine hydrochloride, 0.10 to 5.0 percent of borax, 0.1 to 2.0 percent of boric acid, 0.1 to 10 percent of glycerin, 0.10 to 5.0 percent of sodium bicarbonate, 0.001 to 0.10 percent of vitamin B12, 0.02 to 1.0 percent of tromethamine, 0.01 to 5.0 percent of sucralose, 0.10 to 5.0 percent of peppermint essence and 0.01 to 1.0 percent of sodium benzoate; a proper amount of pharmaceutical caramel color and water for injection is added till to reach the needed weight/volume concentration. All the above components are weighted by weight/volume percentage; the aqueous solution of the composition has the pH value of 6.5 to 9.0. The composition has little thrill to oral mucosa, stable storage for long time and good biological tolerance and has fast and long-lasting curative effect for relieving pain and being anti-inflammatory to the oral inflammation disease.

The invention relates to bleeding-stopping, inflammation-diminishing and pain-relieving nano emulsion for use in minimally invasive beauty treatment therapy and a preparation method thereof. The nano emulsion is prepared from the following raw materials in part by weight: 0.0055 part of thrombase freeze-dried powder, 0.0005 part of epinephrine, 5 parts of calcium chloride, 1 part of sodium chloride, 6 parts of coix seed essence oil, 6 parts of as arum volatile oil, 5 parts of lidocaine hydrochloride, 13.6 parts of isopropyl myristate, 27.6 parts of octoic acid and capric acid polyethylene glycol glyceride, 9.2 parts of polyglycerol-3-dioleate and 26.594 parts of distilled water. The nano emulsion has diversified functions and has bleeding-stopping, inflammation-diminishing and pain-relieving effects, so the complex process of the minimally invasive beauty treatment therapy is simplified. In addition, a nano transdermal technique is adopted to promote the functional components to enterskin effectively, constantly and controllably to produce the bleeding-stopping, inflammation-diminishing and pain-relieving effects; and the toxic and side effects of the nano emulsion can be reducedgreatly.

A composition for local anesthesia which comprises a local anesthetic such as lidocaine hydrochloride as an active ingredient and an agent for sustaining anesthetic action selected from the group consisting of antihistamines such as diphenhydramine hydrochloride or hydroxyzine hydrochloride, and does not substantially contain catecholamines such as epinephrine, which has increased durability of anesthetic action without using catecholamines, and is useful as a safe composition for local anesthesia for performing short-time dental operations such as tooth extraction or oral surgery operations.

The invention relates to a pharmaceutical composition for easing pain. The pharmaceutical composition is prepared from the following components according to the volume ratio: 2% methylthioninium chloride injection, 0.5% bupivacaine hydrochloride injection, 2% lidocaine hydrochloride injection and water for injection, of which the ratio is 2:5:5:16. The pharmaceutical composition relieves pain after being applied to an anorectal postoperative incision, improves local blood circulation, benefits for wound concrescence, contributes to wound bleeding, and reduces secreta. The pharmaceutical composition does not generate systemic adverse reaction after an operation, local edema or necrosis by a clinical test, and has no influence on local granulation tissue growth and wound concrescence; the anus has no abnormity, can smoothly defecate after the wound is repaired, has no untoward effect after follow-up treatment, and is reliable in curative effect. The drug disclosed by the invention removes a local hot pain after methylenum coeruleum is injected, does not generate an anesthesia clearance, is fast to take effect, and takes effect after being injected 2-4 hours; the reversible nerve damage disappears after about 15 days in general; and the requirement of wound growth just can be met.

The invention relates to the technical field of medicine, in particular to an injection powder and injection preparation of a cefoperazone sodium-tazobactam combination. The injection powder and injection preparation comprises cefoperazone sodium, tazobactam combination and lignocaine hydrochloride, wherein the mass ratio of the cefoperazone sodium to the tazobactam combination to the lignocaine hydrochloride is 4:1:(0.01-0.05). Compared with a positive medicament control group, the injection powder and injection preparation of the cefoperazone sodium-tazobactam combination provided by the invention has the advantages of capability of relieving injection pain and remarkable improvement on the curative effect.

The invention relates to a percutaneous absorption film coating agent for treating rheumatoid arthritis and a preparation method thereof. The film coating agent comprises main drugs for treating the rheumatoid arthritis, a drug solvent, a binding agent, a film forming agent and a percutaneous absorption penetration enhancer. The main drugs for treating the rheumatoid arthritis comprise triptolide and analgesic lidocaine hydrochloride for alleviating the pain from the rheumatoid arthritis. The film coating agent has the advantages of complete pharmacological actions, strong pertinence, long-acting pharmacological effects and simple preparation method, and can properly block the main pathological link of the development of the rheumatoid arthritis disease.

A method for preparing a lidocaine hydrochloride mucilage comprises the following steps: a formula amount of ethyl p-hydroxybenzoate is put into purified water which accounts for 25% of the total volume of the ethyl p-hydroxybenzoate, heated and stirred until complete dissolution, added with a formula amount of lidocaine hydrochloride and stirred for dissolution, added with a formula amount of glycerol and stirred evenly; additionally, a formula amount of sodium carboxymethyl cellulose is added to purified water which accounts for 50% of the total volume of the sodium carboxymethyl cellulose, and stirred for complete swelling; the two solutions obtained are mixed evenly, and added with 0.1N sodium hydroxide to adjust the pH value to 6.0-7.0; the monarch drug content of the obtained mucilage is determined; the mucilage is added with water to sufficient amount, mixed evenly and filled, and sterilized by 110 DEG C saturated vapor for 30 minutes; inspected under a lamp and packaged to obtain the finished product. Compared with the prior art, the lidocaine hydrochloride mucilage has the advantages of matching anaesthesia and inspection time, good lubricating property and sterility assurance level.

The invention relates to lidocaine hydrochloride polymeric liposome for topical anesthesia and a preparation method. The preparation method comprises the following steps: dissolving OQLCS (octadecyl-quaternized lysine modified chitosan) and cholesterol in dichloromethane to form an oil phase; completely dissolving lidocaine hydrochloride in deionized water to form a water phase; performing ultrasonic treatment to the oil phase in a power range of between 150 and 200W, adding the water phase, and performing ultrasonic dispersion by using a probe type ultrasonic generator until a semitransparent emulsion is formed to form a dispersion emulsion with uniform water and oil; and performing rotary evaporation to the emulsion on a rotary evaporator at 40 DEG C at a rotating speed of 50r/min, and introducing nitrogen flow into the rotary evaporator for protecting, and filtering through a sterile filter membrane of between 0.2 and 0.4mu m after organic solvent is completely volatilized to obtain the lidocaine hydrochloride polymeric liposome. The encapsulation rate of the liposome to a medicament is between 60 and 85 percent; the grain diameter of the polymeric liposome is between 60 and 180nm, and the surface is positively charged with an electric potential of between 6 and 65mv. The lidocaine hydrochloride polymeric liposome can be directly applied to the surface of skin mucous membrane, or is further prepared to form gel or ointment.

The invention relates to anti-rheumatoid arthritis drug gel containing paclitaxel liposome and a preparation method of the gel. The gel is prepared from main drugs and blank gel, wherein the main drugs comprise paclitaxel liposome and lidocaine hydrochloride; the mass volume ratio of the paclitaxel liposome to lidocaine hydrochloride is 5:100-20:100; and the mass volume ratio of lidocaine hydrochloride to the blank gel is 1:100-5:100. According to the requirements of evidence-based medicine, a drug paclitaxel for treating RA and lidocaine are compatible with each other, the paclitaxel is coated by utilizing a liposome technology, the bioavailability is improved, and the prepared gel suitable for directed use at an affected part is adopted. The gel achieves a treatment effect aiming at the pathogenesis of RA, and pain of a patient suffering from RA can be rapidly relieved. A novel therapy approach is provided for vast patients suffering from RA.

A transdermal paster for treating acute or chronic local pain is prepared from lidocain hydrochloride and methol. It can be used for the ultrasonic-type, ion leading-in type, electric perforating type, or high-pressure gas type medicine supplying system.

The invention relates to a percutaneous absorption biological patch for treating rheumatoid arthritis and preparing method thereof. The biological patch consists of basic remedy treating for the rheumatoid arthritis, medicament solvent, adhesive, biological plaster matrix and percutaneous absorption penetration enhancer. The basic remedies treating for the rheumatoid arthritis include triptolide and analgesics lidocaine hydrochloride alleviating the pain of the rheumatoid arthritis. The biological plaster has comprehensive pharmacological effect, exactly blocks up the main pathology link of development of rheumatoid arthritis, has strong pertinency and lasting pharmacological effect; and can be prepared by using a general method in biological plaster preparing technology field; and the preparing method is simple.

The present invention is directed to a treatment for sunburn and a method for preventing sunburn. One aspect of this invention involves a sunburn treatment comprising one or more polypeptides with an amino acid sequence including KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) for the treatment of the cutaneous inflammation caused by exposure to ultraviolet radiation. The polypeptides are at a level to effectively treat the cutaneous inflammation and are carried by a carrier. The one or more polypeptides can also be a dimer formed from any of the amino acid sequence above. In one preferred embodiment of the invention, the one or more polypeptides are used to prevent sunburn. In another preferred embodiment, the one or more polypeptides are dissolved in a carrier. In another preferred embodiment, the carrier includes aloe vera and lidocaine hydrochloride. In another preferred embodiment of the invention, the one or more polypeptides are dissolved in a liquid that is associated with an absorbent material for application to sunburned skin.

The invention provides lidocaine hydrochloride injection. Each 1000ml of the lidocaine hydrochloride injection is prepared from the following components by weight: 20g of lidocaine hydrochloride (the theoretical weight, and the quantity of lidocaine hydrochloride needs to be determined according to the content as well as the water drying and the purifying condition), and 4.4-5.3 g of sodium chloride. According to the improved lidocaine hydrochloride injection and the preparation method of the lidocaine hydrochloride injection, the prescription composition is simple, and a few kinds of auxiliary materials is adopted, thus the clinical risks caused by lack of iso-osmia of a product are eradicated, and the various index including the pH of the product and related substances are stable and controllable, and meet the requirements in the exposure draft of the lidocaine hydrochloride injection in the China pharmacopeia 2015; the lidocaine hydrochloride injection is suitable for clinical application, and the product is safe and effective. A preparation method is simple, new cost is not increased, and the lidocaine hydrochloride injection is suitable for large-scale industrial production and has a large application value.

The invention discloses a nutritional injection for neck skin repair. Every 120 ml of the nutritional injection contains 95-110 ml of a sodium chloride solution, 5-10 ml of dimethylaminoethanol, 1-5 ml of cationic hyaluronic acid, 5-10 ml of a lidocaine hydrochloride injection and 110-120 million units of fibroblasts. By injection of a composite fiber nutrient solution, autologous tissues are self-healed and regenerated, and the effect is more natural. Meanwhile, collagen and elastin are continuously secreted, and the effect is more durable.

Provided are kits for collecting samples from a person for DNA (Deoxyribonucleic acid) testing. The kits can optionally also allow for collection of a urine sample. Components of the kits can include lid local anesthetic such as lidocaine hydrochloride, an item that allows for cleaning the mouth, such as mouthwash, a tool for removing DNA such as buccal swabsticks, a container for collecting urine, such as a urine cup, a pair of gloves, a face mask, and a CSR wrap. DNA samples are collected from the buccal area by scraping the area with a buccal swabstick provided in the kit.

The invention relates to a radionuclide pollution decontamination agent and a preparation method and an application thereof. The decontaminant comprises the following components by mass percentage: 1.0%-20% of EDTA.Na2, 0.1%-0.4% of carboxymethyl chitosan, 0.05%-0.3% of sodium alginate, 0.5%-2.0% of lidocaine hydrochloride, and balance of pure water or phosphate buffer, wherein a pH value is 6.9-7.0. The preparation method comprises the following steps: EDTA-Na2, carboxymethyl chitosan, sodium alginate and lidocaine hydrochloride are accurately weighed according to the proportion, the EDTA-Na2is heated and dissolved under alkaline conditions, and then the carboxymethyl chitosan and sodium alginate are dissolved, and then the two are mixed and stirred uniformly, a lidocaine hydrochloride solution is added, the pH is adjusted to 6.7-6.9 with HCl, the material is dissolved while stirring, and metering a volume. The decontamination agent has a chelate adsorption function on a plurality ofradionuclides, has no toxic and side effects, and can be used as the low-toxic and high-efficiency radionuclide pollution decontamination agent.